Dovitinib Plus an Aromatase Inhibitor for Metastatic Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Dovitinib|DRUG: Aromatase Inhibitors
Sponsor: Georgetown University
Collaborators: Novartis Pharmaceuticals